These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 23056179

  • 1. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ.
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [Abstract] [Full Text] [Related]

  • 2. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.
    Clin Cancer Res; 2014 Nov 15; 20(22):5756-67. PubMed ID: 25316808
    [Abstract] [Full Text] [Related]

  • 3. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
    Dong M, Xiao Q, Hu J, Cheng F, Zhang P, Zong W, Tang Q, Li X, Mao F, He Y, Yu X, Wan F, Lei T, Guo D, Wang B.
    Cancer Gene Ther; 2020 Dec 15; 27(12):878-897. PubMed ID: 31988476
    [Abstract] [Full Text] [Related]

  • 4. ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.
    Aljohani H, Koncar RF, Zarzour A, Park BS, Lee SH, Bahassi el M.
    Oncotarget; 2015 Aug 21; 6(24):20388-95. PubMed ID: 25978031
    [Abstract] [Full Text] [Related]

  • 5. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
    Acquaviva J, Jun HJ, Lessard J, Ruiz R, Zhu H, Donovan M, Woolfenden S, Boskovitz A, Raval A, Bronson RT, Pfannl R, Whittaker CA, Housman DE, Charest A.
    Cancer Res; 2011 Dec 01; 71(23):7198-206. PubMed ID: 21987724
    [Abstract] [Full Text] [Related]

  • 6. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
    Ma Y, Tang N, Thompson RC, Mobley BC, Clark SW, Sarkaria JN, Wang J.
    Clin Cancer Res; 2016 Apr 01; 22(7):1767-76. PubMed ID: 26561558
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J, Torka R, Korsing S, Radke J, Krementeskaia I, Nieminen M, Bai X, Ullrich A, Heppner F, Vajkoczy P.
    Oncotarget; 2016 Mar 01; 7(9):9876-89. PubMed ID: 26848524
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.
    Neuro Oncol; 2017 Oct 19; 19(11):1469-1480. PubMed ID: 28379424
    [Abstract] [Full Text] [Related]

  • 10. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
    Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B.
    Neuro Oncol; 2010 Aug 19; 12(8):822-33. PubMed ID: 20179017
    [Abstract] [Full Text] [Related]

  • 11. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
    Hui EP, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT.
    Invest New Drugs; 2011 Dec 19; 29(6):1123-31. PubMed ID: 20467883
    [Abstract] [Full Text] [Related]

  • 12. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D, Wang S, Wu S, Saito N, Zheng S, Gao F, Kaul I, Setoguchi M, Nakayama K, Koyama K, Shiose Y, Sulman EP, Hirota Y, Yung WKA.
    Oncotarget; 2017 Mar 28; 8(13):21741-21753. PubMed ID: 28423515
    [Abstract] [Full Text] [Related]

  • 13. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
    Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, Mischel PS, Kohmura E.
    J Clin Invest; 2015 Apr 28; 125(4):1591-602. PubMed ID: 25798620
    [Abstract] [Full Text] [Related]

  • 14. The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.
    D'Amico R, Lei L, Kennedy BC, Sisti J, Ebiana V, Crisman C, Christensen JG, Gil O, Rosenfeld SS, Canoll P, Bruce JN.
    Neurol Res; 2012 Apr 28; 34(3):252-61. PubMed ID: 22449730
    [Abstract] [Full Text] [Related]

  • 15. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
    Jiang P, Mukthavaram R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, Kesari S.
    J Transl Med; 2014 Jan 17; 12():13. PubMed ID: 24433351
    [Abstract] [Full Text] [Related]

  • 16. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK, Shonka N.
    J Exp Clin Cancer Res; 2019 Jun 18; 38(1):266. PubMed ID: 31215502
    [Abstract] [Full Text] [Related]

  • 17. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.
    Mol Cancer Ther; 2009 Jul 18; 8(7):1751-60. PubMed ID: 19584231
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
    Pozo N, Zahonero C, Fernández P, Liñares JM, Ayuso A, Hagiwara M, Pérez A, Ricoy JR, Hernández-Laín A, Sepúlveda JM, Sánchez-Gómez P.
    J Clin Invest; 2013 Jun 18; 123(6):2475-87. PubMed ID: 23635774
    [Abstract] [Full Text] [Related]

  • 19. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
    de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS.
    Neuro Oncol; 2007 Oct 18; 9(4):412-23. PubMed ID: 17622648
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
    Liu S, Tang Y, Yuan X, Yuan D, Liu J, Li B, Li Y.
    Invest New Drugs; 2018 Dec 18; 36(6):961-969. PubMed ID: 29508248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.